Ailing pharma sector needs uniform drug standards: Ranbaxy

Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.

Strides Arcolab arm in JV with Pfenex for biosimilar drugs

Strides Arcolab‘s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market

Sale proceeds to help cut debt, repay FCCB: Strides Arcolab

Strides Arcolab aims to use the funds received through the sale of its Southeast Asian and Australian units to repay foreign currency convertible bondholders and reduce the debt, says group chief executive and vice chairman Arun Kumar.

Strides Arcolab eyes 30-35% growth in current year

In an interview with CNBC-TV18, Arun Kumar, Vice Chairman and MD, Strides Arcolab said Polymyxin is a small molecule, but currently it is in the shortage list of products. He further said the company will grow 30-35% in the current year.

Strides, Pfizer to deal post US FDA nod on Oncology unit

Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.

Strides Arcolab expects more approvals from US FDA soon

In an interview with CNBC-TV18, Arun Kumar, Group CEO and Vice Chairman, Strides Arcolab spoke on the development and the way forward for the company.